SARS-CoV InfectionMIOCOVIDNCT04959773
Muscle Weakness in COVID-19 Patients
An observational study of SARS-CoV Infection and Covid19, run by University of Pavia at 1 site in Italy.
Trial summary
Although the Covid-19 infection mainly manifests itself with respiratory symptoms, as early as two months after the onset of the pandemic, the presence of other symptoms, including muscle ones, became clear. Read more about this study
- Who is it for?
- Ages 35 to 70 years
- Conditions the study is for
- SARS-CoV Infection, Covid19, Muscle Weakness
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 15 Nov 2020to 30 Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 70 years
- All sexes
- Adult, Older adult
Study population: Patients will be divided into three Groups : * COVID+ with exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. * COVID+ without exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. * CTRL Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)).
Who may be able to join
- -
Who cannot join
- presence of cardiovascular, neurological and metabolic disorders.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Potential Mechanisms of Long-term Muscle Weakness and Decreased Exercise Tolerance in Patients Infected by SARS-COV-2
Although the Covid-19 infection mainly manifests itself with respiratory symptoms, as early as two months after the onset of the pandemic, the presence of other symptoms, including muscle ones, became clear. With the disappearance of the emergency and the advancement of knowledge, medium- and long-term effects have been reported at the level of different organs and systems. Many patients, after several months from infection, report intolerance to exercise and many suffer from pain and muscle weakness. No studies has been carried out on the muscular consequences of the infection and on their possible contribution to intolerance to exercise. Since skeletal muscle possesses the ACE2 receptor (Angiotensin converting enzyme 2) to which SARS-Cov-2 binds, it follows that the involvement of the skeletal muscle could be due not only to the secondary effects of the infection (e.g. reduced oxygen supply from persistent lung disease, perfusion defects from cardiovascular defects and vascular damage), but also to the direct action of virus (SARS-Cov-2 myositis).
The general purpose of the research is to quantify the spread of symptoms and signs of muscle weakness and pain among the patient population welcomed at the Cardiorespiratory Rehabilitation Department of the Alexandria Hospital which have been suffering from SARS-CoV-2, being discharged and healed for more than two months, and define the possible contribution of muscular modifications to exercise intolerance.
Read the detailed description
Exercise intolerance and muscle weakness have important consequences on the quality of life of healed patients and significant clinical implications: increased risk of falls and bone fractures, physical deconditioning and increased risk of chronic lung impairment and other diseases. Physical deconditioning and muscle weakness are, in fact, among the recognized risks of chronic pathologies. The identification of any covid-19 myopathy and its pathogenesis it would be of great importance to define adequate measures to counter it, for example through the prescription of physical exercise, limit the clinical consequences, improve the quality of life for many patients and decrease the cost for the National Health System. The present study aims to assess the frequency of easy fatigue, weakness and muscle pain in the population at the time of the onset of SARS-CoV-2 infection and after 2-3 months after healing. Moreover, as secondary outcome, it will evaluate the presence of objective signs of muscle involvement of theSARS-CoV-2 infections 2-3 months after recovery, quantifying the presence of myopathic structural changes and the causes of any muscle damage.
The study is a pilot single center clinical study, with non-pharmacological intervention, aimed at improve of clinical practice as an integral part of non-purpose health care industrial companies in accordance with the D.M. 17-12-2004 (No-Profit Trial).
The screening of eligible patients will be carried out by consulting the records paper-based clinics of patients belonging to the SSD Cardiorespiratory Rehabilitation of the Hospital of SS Antonio and Biagio and Cesare Arrigo in Alessandria. To eligible patients will be then submitted the information and consent document to participate in the study during the routine outpatient visits planned for these subjects. If following the explanations of the Investigator regarding the experimentation and evaluation of the document informative the patient decides to join the study and proceed with the following phases.
In-vivo physiological evaluation will be performed in suitable premises of the Center Interdepartmental Research Department of Biology and Sports Medicine of the University of Pavia equipped with the necessary equipment for first aid and in the presence of a doctor specialist in cardiology or related disciplines, with constant monitoring of vital parameters (arterial saturation, blood pressure and heart rate) and signal 12-lead electrocardiography. It will consist of an incremental cycle ergometer test until exhaustion; exhaustion will be defined by the patient's inability to maintain an adequate pedaling frequency, from reaching an equal heart rate value at least 85% of the predicted maximum heart rate or from a perception level fatigue (Borg scale) greater than 17. Patients will be asked before the assessment to become familiar with the instrumentation and with the researchers involved, by making briefs evidence. In the event that the patient / control subject complains of symptoms of fatigue, headache, dizziness, precordialgia or increased blood pressure during the exercise, this will be immediately suspended. In the presence of cardiovascular diseases or internist or in any case of serious general conditions the patient / control subject will not be enrolled in the study. Incremental testing and physiological assessments are used by several years from the research group of Physiology both on healthy volunteers and on patients with different pathologies (patients with neuromuscular pathologies, patients with heart failure, heart transplant patients, bronchopneumopathic patients) with no evidence of events adverse (Lanfranconi et al., 2006; Grassi et al., 2009; Marzorati et al., 2012a; Marzorati et al., 2012b; Mezzani et al., 2012; Mezzani et al., 2013; Grassi et al., 2020).
During the physiological assessment tests the following measurements will be performed:
- determination of pulmonary ventilation (VE), oxygen consumption (VO2) e of the production of carbon dioxide (VCO2) breath by breath by calorimetry indirect (Vyntus, Carefusion);
- detection of heart rate (HR) by electrocardiographic signal at 12 derivations
- determination of systolic (Gs) and cardiac (Q) output by impedance analysis trans-thoracic (Physioflow, Manatec Biomedical);
- measurements of the concentration of lactic acid ([La] b) in 20 microliters of capillary blood obtained from the earlobe or fingertip of the hand (Biosen C-line, EKF) at rest and after exercise;
- determination of oxygenation modifications of the vastus lateral muscle ([deoxy (Hb + Mb)]) estimated by quasi-infrared spectroscopy (NIRS, Portamon, Artinis). Moreover, immediately after a knee flexion-extension exercise a series of 10-18 short (5-10s) occlusions using a pressure cuff applied to the root of the thigh. To minimize the discomfort of the study participants two successive occlusions will be separated by a time interval of 5s-20s (for example 5s for occlusions from 1 to 5, 10s for occlusions from 6 to 10, 15-20s for occlusions from 11 to 15). A transient interruption of blood flow will be performed in order to achieve complete deoxygenation at the level of the investigated muscle (maximum time 3 minutes). The level-positioned NIRS probe of the vastus lateral muscle will allow to estimate the maximum oxidative capacity of the muscle.
Finally, to evaluate some muscular contractile properties, 3 maximum voluntary contractions (MVC) lasting 5 seconds will be required. Each contraction will be separated from the subsequent by an adequate recovery period.
Muscle biopsies will be performed at the Salvatore Maugeri IRCCS Foundation in Pavia (performed by Dr. Danilo Miotti) or at the Cardiorespiratory Rehabilitation SSD of the Alessandria Hospital (performed by Dr. Biagio Polla) through the concotome tool. Muscle biopsy used routinely for the diagnosis of pathologies muscles in neurology and, for decades now, for the study of physiological adaptations and pathological changes in human skeletal muscle. The human research projects of Muscle Plasticity Laboratory of the Department of Molecular Medicine used, with no evidence of adverse events, hundreds of biopsies obtained from healthy young subjects, sedentary and trained subjects, elderly subjects, subjects undergoing drug treatment (steroids), pneumopathic subjects in collaboration with ICS-Maugeri Pavia since 1994.
The analyzes on the biopsy material will be performed at the Department of Medicine Molecular of the University of Pavia, Human Physiology unit, Plasticity laboratory muscle, with the aim of evaluating the presence of a myopathic condition with modification quantitative and / or qualitative of skeletal muscle tissue. The laboratory has a vast experience in obtaining and analyzing human biopsy tissue having developed this approach among the first at an international level since 1996.
- Conditions
- SARS-CoV Infection, Covid19, Muscle Weakness, Exercise Intolerance
- Medical subject headings
- Severe Acute Respiratory Syndrome, COVID-19, Muscle Weakness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COVID+ with exercise intolerance | Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. general conditions. | |
| COVID+ without exercise intolerance | Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. | |
| Control healthy subjects (CTRL) | Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional status
Post-COVID-19 Functional Status scale
Measured: at least 2 months after infection
Perceived quality of life by EQ-5D-5L
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Measured: at least 2 months after infection
Exercise intolerance
Maximal oxygen consumption during incremental test
Measured: at least 2 months after infection
Muscle weakness
Reduced muscle force during isometric contraction
Measured: at least 2 months after infection
Pulmonary function
Spirometry and DLCO capacity
Measured: at least 2 months after infection
Secondary outcomes (4)
Muscle fatiguability
Central and peripheral indexes of fatigue after an isotonic exercise
Measured: at least 2 months after infection
Histology and morphology of skeletal muscle
The muscle sections will be stained with: 1) Hoechst nuclear dye for evaluating the presence of nucleated center cells and 2) Hematoxylin and Eosin (H\&E) for measuring the area of the cross section of the individual muscle fibers (CSA) and to reveal morphological alterations. The morphological analysis should first demonstrate the presence of atrophy of individual muscle fibers. From the morphological analysis it will also be possible to highlight the presence of inflammatory infiltrates, the presence of core nucleated cells and other signs of structural alteration.
Measured: at least 2 months after infection
Single muscle fiber mechanics
Functional analyzes will be performed on single muscle fibers and on isolated myosin.
The absolute isometric force (Po), the specific isometric force (Po / CSA) and the no-load shortening rate (Vo) of the individual muscle fibers will be determined with the slack test technique. The fibers, chemically deprived of the cell membrane through exposure to detergent (Triton X 100), will be stimulated by exposure to a solution containing Ca2 + and ATP ions. At the end of the functional experiment, the fibers will be collected and typed through the analysis of the isoform content of the myosin heavy chain (MHC).
Measured: at least 2 months after infection
Ex-vivo muscle oxidative function
Through molecular analyzes it will be possible to investigate the mechanisms underlying the possible myopathic condition. The following molecular investigations will be performed with Real Time-PCR (RT-PCR) and Western Blot (WB) techniques: activation of the signaling pathways of synthesis and protein degradation (IGF-1 / Akt / mTOR; ubiquitin proteosome system, autophagy ); apoptosis; mitochondrial dynamics; redox state.
Measured: at least 2 months after infection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2021
- Study start15 Nov 2020
- Primary completion15 May 2022
- Study completion30 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pavia
- Sponsor type
- University, hospital or other
- Collaborators
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
- Responsible party
- Principal investigator, Simone Porcelli, University of Pavia
- Investigators
- Biagio Polla, MD, Principal investigator, AO SS Alessandria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04959773
- Sponsor's protocol ID
- UPavia-MIOCOVID
- Acronym
- MIOCOVID
- Status last verified
- May 2023
- First submitted
- 8 Apr 2021
- Last updated
- 11 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Potential Mechanisms of Long-term Muscle Weakness and Decreased Exercise Tolerance in Patients Infected by SARS-COV-2
- ClinicalTrials.gov ID
- NCT04959773
- Acronym / sponsor ID
- MIOCOVID / UPavia-MIOCOVID
- Conditions
- SARS-CoV Infection, Covid19, Muscle Weakness, Exercise Intolerance
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of PaviaUniversity, hospital or other
- Collaborators
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
- Study start
- 15 Nov 2020 (actual)
- Primary completion
- 15 May 2022 (actual)
- Study completion
- 30 Jan 2023 (actual)
- First posted
- 13 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although the Covid-19 infection mainly manifests itself with respiratory symptoms, as early as two months after the onset of the pandemic, the presence of other symptoms, including muscle ones, became clear. With the disappearance of the emergency and the advancement of knowledge, medium- and long-term effects have been reported at the level of different organs and systems. Many patients, after several months from infection, report intolerance to exercise and many suffer from pain and muscle weakness. No studies has been carried out on the muscular consequences of the infection and on their possible contribution to intolerance to exercise. Since skeletal muscle possesses the ACE2 receptor (Angiotensin converting enzyme 2) to which SARS-Cov-2 binds, it follows that the involvement of the skeletal muscle could be due not only to the secondary effects of the infection (e.g. reduced oxygen supply from persistent lung disease, perfusion defects from cardiovascular defects and vascular damage), but also to the direct action of virus (SARS-Cov-2 myositis).
The general purpose of the research is to quantify the spread of symptoms and signs of muscle weakness and pain among the patient population welcomed at the Cardiorespiratory Rehabilitation Department of the Alexandria Hospital which have been suffering from SARS-CoV-2, being discharged and healed for more than two months, and define the possible contribution of muscular modifications to exercise intolerance.
Detailed description
Exercise intolerance and muscle weakness have important consequences on the quality of life of healed patients and significant clinical implications: increased risk of falls and bone fractures, physical deconditioning and increased risk of chronic lung impairment and other diseases. Physical deconditioning and muscle weakness are, in fact, among the recognized risks of chronic pathologies. The identification of any covid-19 myopathy and its pathogenesis it would be of great importance to define adequate measures to counter it, for example through the prescription of physical exercise, limit the clinical consequences, improve the quality of life for many patients and decrease the cost for the National Health System. The present study aims to assess the frequency of easy fatigue, weakness and muscle pain in the population at the time of the onset of SARS-CoV-2 infection and after 2-3 months after healing. Moreover, as secondary outcome, it will evaluate the presence of objective signs of muscle involvement of theSARS-CoV-2 infections 2-3 months after recovery, quantifying the presence of myopathic structural changes and the causes of any muscle damage.
The study is a pilot single center clinical study, with non-pharmacological intervention, aimed at improve of clinical practice as an integral part of non-purpose health care industrial companies in accordance with the D.M. 17-12-2004 (No-Profit Trial).
The screening of eligible patients will be carried out by consulting the records paper-based clinics of patients belonging to the SSD Cardiorespiratory Rehabilitation of the Hospital of SS Antonio and Biagio and Cesare Arrigo in Alessandria. To eligible patients will be then submitted the information and consent document to participate in the study during the routine outpatient visits planned for these subjects. If following the explanations of the Investigator regarding the experimentation and evaluation of the document informative the patient decides to join the study and proceed with the following phases.
In-vivo physiological evaluation will be performed in suitable premises of the Center Interdepartmental Research Department of Biology and Sports Medicine of the University of Pavia equipped with the necessary equipment for first aid and in the presence of a doctor specialist in cardiology or related disciplines, with constant monitoring of vital parameters (arterial saturation, blood pressure and heart rate) and signal 12-lead electrocardiography. It will consist of an incremental cycle ergometer test until exhaustion; exhaustion will be defined by the patient's inability to maintain an adequate pedaling frequency, from reaching an equal heart rate value at least 85% of the predicted maximum heart rate or from a perception level fatigue (Borg scale) greater than 17. Patients will be asked before the assessment to become familiar with the instrumentation and with the researchers involved, by making briefs evidence. In the event that the patient / control subject complains of symptoms of fatigue, headache, dizziness, precordialgia or increased blood pressure during the exercise, this will be immediately suspended. In the presence of cardiovascular diseases or internist or in any case of serious general conditions the patient / control subject will not be enrolled in the study. Incremental testing and physiological assessments are used by several years from the research group of Physiology both on healthy volunteers and on patients with different pathologies (patients with neuromuscular pathologies, patients with heart failure, heart transplant patients, bronchopneumopathic patients) with no evidence of events adverse (Lanfranconi et al., 2006; Grassi et al., 2009; Marzorati et al., 2012a; Marzorati et al., 2012b; Mezzani et al., 2012; Mezzani et al., 2013; Grassi et al., 2020).
During the physiological assessment tests the following measurements will be performed:
- determination of pulmonary ventilation (VE), oxygen consumption (VO2) e of the production of carbon dioxide (VCO2) breath by breath by calorimetry indirect (Vyntus, Carefusion);
- detection of heart rate (HR) by electrocardiographic signal at 12 derivations
- determination of systolic (Gs) and cardiac (Q) output by impedance analysis trans-thoracic (Physioflow, Manatec Biomedical);
- measurements of the concentration of lactic acid ([La] b) in 20 microliters of capillary blood obtained from the earlobe or fingertip of the hand (Biosen C-line, EKF) at rest and after exercise;
- determination of oxygenation modifications of the vastus lateral muscle ([deoxy (Hb + Mb)]) estimated by quasi-infrared spectroscopy (NIRS, Portamon, Artinis). Moreover, immediately after a knee flexion-extension exercise a series of 10-18 short (5-10s) occlusions using a pressure cuff applied to the root of the thigh. To minimize the discomfort of the study participants two successive occlusions will be separated by a time interval of 5s-20s (for example 5s for occlusions from 1 to 5, 10s for occlusions from 6 to 10, 15-20s for occlusions from 11 to 15). A transient interruption of blood flow will be performed in order to achieve complete deoxygenation at the level of the investigated muscle (maximum time 3 minutes). The level-positioned NIRS probe of the vastus lateral muscle will allow to estimate the maximum oxidative capacity of the muscle.
Finally, to evaluate some muscular contractile properties, 3 maximum voluntary contractions (MVC) lasting 5 seconds will be required. Each contraction will be separated from the subsequent by an adequate recovery period.
Muscle biopsies will be performed at the Salvatore Maugeri IRCCS Foundation in Pavia (performed by Dr. Danilo Miotti) or at the Cardiorespiratory Rehabilitation SSD of the Alessandria Hospital (performed by Dr. Biagio Polla) through the concotome tool. Muscle biopsy used routinely for the diagnosis of pathologies muscles in neurology and, for decades now, for the study of physiological adaptations and pathological changes in human skeletal muscle. The human research projects of Muscle Plasticity Laboratory of the Department of Molecular Medicine used, with no evidence of adverse events, hundreds of biopsies obtained from healthy young subjects, sedentary and trained subjects, elderly subjects, subjects undergoing drug treatment (steroids), pneumopathic subjects in collaboration with ICS-Maugeri Pavia since 1994.
The analyzes on the biopsy material will be performed at the Department of Medicine Molecular of the University of Pavia, Human Physiology unit, Plasticity laboratory muscle, with the aim of evaluating the presence of a myopathic condition with modification quantitative and / or qualitative of skeletal muscle tissue. The laboratory has a vast experience in obtaining and analyzing human biopsy tissue having developed this approach among the first at an international level since 1996.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| COVID+ with exercise intolerance | – | –Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. general conditions. |
| COVID+ without exercise intolerance | – | –Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. |
| Control healthy subjects (CTRL) | – | –Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. |
Who may qualify
- Ages
- 35 to 70 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients will be divided into three Groups : * COVID+ with exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. * COVID+ without exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. * CTRL Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)).
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (1 listed)
- presence of cardiovascular, neurological and metabolic disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Functional status
Time frame: at least 2 months after infection
Post-COVID-19 Functional Status scale
Perceived quality of life by EQ-5D-5L
Time frame: at least 2 months after infection
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Exercise intolerance
Time frame: at least 2 months after infection
Maximal oxygen consumption during incremental test
Muscle weakness
Time frame: at least 2 months after infection
Reduced muscle force during isometric contraction
Pulmonary function
Time frame: at least 2 months after infection
Spirometry and DLCO capacity
4 secondary outcomes
Muscle fatiguability
Time frame: at least 2 months after infection
Histology and morphology of skeletal muscle
Time frame: at least 2 months after infection
Single muscle fiber mechanics
Time frame: at least 2 months after infection
Ex-vivo muscle oxidative function
Time frame: at least 2 months after infection
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2023.
- Individual participant dataSharing planned: No
Related trials for SARS-CoV Infection
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Not yet recruiting
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
Respiratory Viral Infections, Influenza
Recruiting
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
COVID-19, Long COVID
Active, not recruiting
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
SARS-CoV Infection
Active, not recruiting
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
SARS CoV 2 Infection, Influenza A Virus Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Biagio Polla, MD principal investigator
AO SS Alessandria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SARS-CoV Infection and Covid19, run by University of Pavia at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional status (time frame: at least 2 months after infection). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2023.